LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 127

Search options

  1. Article: Use of computational electrocardiographic mapping to guide successful surgical cryoablation of a premature ventricular contraction originating near an intramural anomalous coronary artery.

    Jackson, Candace L / Krummen, David E / Carazo, Matthew / Feld, Gregory / Artrip, Jonathan / Ho, Gordon

    HeartRhythm case reports

    2024  Volume 10, Issue 3, Page(s) 231–233

    Language English
    Publishing date 2024-01-12
    Publishing country United States
    Document type Case Reports
    ZDB-ID 2834871-0
    ISSN 2214-0271
    ISSN 2214-0271
    DOI 10.1016/j.hrcr.2024.01.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: A simple improvement on existing technology to enhance transseptal puncture and left atrial access using large diameter sheaths for mapping, ablation, and LAA occlusion procedures.

    Feld, Gregory K / Hsu, Jonathan C

    Journal of cardiovascular electrophysiology

    2021  Volume 32, Issue 3, Page(s) 735–736

    MeSH term(s) Atrial Appendage/diagnostic imaging ; Atrial Appendage/surgery ; Heart Atria/diagnostic imaging ; Heart Atria/surgery ; Humans ; Punctures ; Technology
    Language English
    Publishing date 2021-02-02
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 1025989-2
    ISSN 1540-8167 ; 1045-3873
    ISSN (online) 1540-8167
    ISSN 1045-3873
    DOI 10.1111/jce.14899
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2863: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Implementing Opt-Out HIV Testing in the Alameda County Jails.

    Feld, Samantha / Steele, Jessica / Klinedinst, Shailey / Delgadillo, Holvis / Garcia, Jonathan / Hinojosa, Lorenzo / Winters, Amanda

    Journal of correctional health care : the official journal of the National Commission on Correctional Health Care

    2023  Volume 29, Issue 2, Page(s) 156–162

    Abstract: Incorporating routine opt-out HIV testing in correctional settings is a critical component of an effective strategy to end the HIV/AIDS epidemic. Between 2012 and 2017, Alameda County jails implemented opt-out HIV testing to identify new cases, link ... ...

    Abstract Incorporating routine opt-out HIV testing in correctional settings is a critical component of an effective strategy to end the HIV/AIDS epidemic. Between 2012 and 2017, Alameda County jails implemented opt-out HIV testing to identify new cases, link those who were newly diagnosed to care, and reengage those who were previously diagnosed but not in care. Over a 6-year period, 15,906 tests were conducted, with a positivity rate of 0.55% for both newly diagnosed cases and previously diagnosed but out of care. Nearly 80% of those who tested positive were linked to care within 90 days. The high positivity and successful linkage and reengagement with care underscores the need to support HIV testing programs in correctional settings.
    MeSH term(s) Humans ; Prisons ; Prisoners ; Jails ; HIV Infections/diagnosis ; HIV Infections/epidemiology ; HIV Testing ; Mass Screening
    Language English
    Publishing date 2023-02-20
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 2233559-6
    ISSN 1940-5200 ; 1078-3458
    ISSN (online) 1940-5200
    ISSN 1078-3458
    DOI 10.1089/jchc.20.05.0032
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine.

    Feld, Jonathan / Tremblay, Douglas / Navada, Shyamala C / Silverman, Lewis R

    Leukemia & lymphoma

    2022  Volume 64, Issue 3, Page(s) 525–539

    Abstract: Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are devastating diseases that frequently rely on the use of parenteral hypomethylating agents (HMAs), either as monotherapy or in combination, as first-line treatment for many patients. Two ...

    Abstract Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are devastating diseases that frequently rely on the use of parenteral hypomethylating agents (HMAs), either as monotherapy or in combination, as first-line treatment for many patients. Two new oral HMAs, decitabine/cedazuridine (DC) for use in place of azacitidine or decitabine in MDS, and azacitidine (CC-486) for use as maintenance treatment in AML, were recently approved by the FDA. We will discuss the development of these oral HMAs, including the advantages/disadvantages in transitioning to oral HMAs and an in depth look at the pivotal phase III trials that led to their FDA approval - ASCERTAIN for DC and QUAZAR-AML-001 for CC-486. We also review how these agents have been and are being studied in other malignancies, and examine the future role that these exciting novel agents will play in both MDS and AML.
    MeSH term(s) Humans ; Decitabine/therapeutic use ; Antimetabolites, Antineoplastic/therapeutic use ; Azacitidine/therapeutic use ; Myelodysplastic Syndromes/drug therapy ; Myelodysplastic Syndromes/pathology ; Leukemia, Myeloid, Acute/drug therapy
    Chemical Substances cc-486 ; Decitabine (776B62CQ27) ; Antimetabolites, Antineoplastic ; Azacitidine (M801H13NRU)
    Language English
    Publishing date 2022-11-12
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1042374-6
    ISSN 1029-2403 ; 1042-8194
    ISSN (online) 1029-2403
    ISSN 1042-8194
    DOI 10.1080/10428194.2022.2142051
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2997: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Exclusion of Acute Myeloid Leukemia Patients with Central Nervous System Involvement from Clinical Trials: An Analysis of the National Institutes of Health Clinical Trials Registry from 2012-2022.

    Sastow, Dahniel / Van Hyfte, Grace / Feld, Jonathan / Kremyanskaya, Marina / Mascarenhas, John / Tremblay, Douglas

    Acta haematologica

    2023  , Page(s) 1

    Abstract: Introduction: Central nervous system (CNS) involvement in acute myeloid leukemia (AML) can be successfully treated with intrathecal chemotherapy and carries debatable prognostic impact. However, patients with CNS involvement are commonly excluded from ... ...

    Abstract Introduction: Central nervous system (CNS) involvement in acute myeloid leukemia (AML) can be successfully treated with intrathecal chemotherapy and carries debatable prognostic impact. However, patients with CNS involvement are commonly excluded from clinical trials at an unknown rate. We systematically evaluated exclusion criteria of AML clinical trials based on CNS involvement and determined associations with clinical trial characteristics.
    Methods: The National Institutes of Health Clinical Trials Registry was searched for interventional adult AML trials between 2012-2022 that were phase I, II, or III and relevant trial characteristics were extracted.
    Results: 1270 trials were included in the analysis with 790 trials (62.1%) explicitly excluding CNS involvement. There was no significant change in rates of CNS exclusion over the past decade. CNS exclusion was higher in trials that included the non-transplant population compared to trials exclusive to the transplant population (66.9% vs. 43.8%, p<0.01). Non-transplant trials were also more likely to exclude patients with a history of or ambiguous timing of CNS involvement (p<0.01). Phase III trials were associated with more liberal definitions of CNS exclusion (history or ambiguous timing) as compared to phase I and II trials that had higher rates of excluding patients with only active CNS involvement (P<0.01).
    Conclusion: A majority of AML clinical trials, particularly in the non-transplant setting, exclude patients with CNS involvement. Many of these trials, most notably phase 3 trials, exclude patients not only with active, but any history of CNS involvement. Further research is needed to determine optimal management of these patients in order to increase representation in large clinical trials.
    Language English
    Publishing date 2023-09-26
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 80008-9
    ISSN 1421-9662 ; 0001-5792
    ISSN (online) 1421-9662
    ISSN 0001-5792
    DOI 10.1159/000533819
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ud II Zs.145: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Exercise-induced arrhythmias.

    Hoffmayer, Kurt S / Han, Frederick T / Hsu, Jonathan C / Feld, Gregory K / Scheinman, Melvin M

    Heart rhythm

    2022  Volume 19, Issue 7, Page(s) 1214–1216

    MeSH term(s) Arrhythmias, Cardiac/etiology ; Arrhythmias, Cardiac/therapy ; Electrocardiography ; Humans
    Language English
    Publishing date 2022-06-28
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 2229357-7
    ISSN 1556-3871 ; 1547-5271
    ISSN (online) 1556-3871
    ISSN 1547-5271
    DOI 10.1016/j.hrthm.2021.09.012
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6278: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Discontinuation Syndrome With JAK2 Selective Agents: Case Presentation and Mechanistic Insights.

    Handa, Shivani / Farina, Kyle A / Becker, Michelle / Kelly, Brianna / Yu, Ashley / Feld, Jonathan / Tremblay, Douglas / Marcellino, Bridget K / Salib, Christian / Mascarenhas, John / Shih, Alan H

    JCO precision oncology

    2024  Volume 8, Page(s) e2300234

    Abstract: We report the first case of pacritinib-withdrawal syndrome with in vitro elucidation of underlying mechanisms. ...

    Abstract We report the first case of pacritinib-withdrawal syndrome with in vitro elucidation of underlying mechanisms.
    MeSH term(s) Humans ; Primary Myelofibrosis ; Bridged-Ring Compounds ; Pyrimidines ; Janus Kinase 2/genetics
    Chemical Substances Bridged-Ring Compounds ; Pyrimidines ; JAK2 protein, human (EC 2.7.10.2) ; Janus Kinase 2 (EC 2.7.10.2)
    Language English
    Publishing date 2024-01-31
    Publishing country United States
    Document type Case Reports ; Journal Article
    ISSN 2473-4284
    ISSN (online) 2473-4284
    DOI 10.1200/PO.23.00234
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  8. Article ; Online: Myelo-deception: Luspatercept & TGF-Beta ligand traps in myeloid diseases & anemia.

    Feld, Jonathan / Navada, Shyamala C / Silverman, Lewis R

    Leukemia research

    2020  Volume 97, Page(s) 106430

    Abstract: Myelodysplastic syndromes (MDS) encompass a clinically heterogenous group of diseases defined by a clonal bone marrow failure state. Patients with lower-risk MDS primarily suffer from the consequences of anemia, with a subset having increased risks of ... ...

    Abstract Myelodysplastic syndromes (MDS) encompass a clinically heterogenous group of diseases defined by a clonal bone marrow failure state. Patients with lower-risk MDS primarily suffer from the consequences of anemia, with a subset having increased risks of bleeding and infection. There are few good therapeutic options for this patient population, as patients are dependent on cytokine support to improve hematopoiesis. Our review will discuss luspatercept, a transforming growth factor (TGF)-Beta ligand trap, the first new Food & Drug Administration (FDA)-approved treatment in MDS in over a decade. We will explore the different TGF-Beta ligand traps that have been developed for a number of diseases, with a focus on myeloid malignancies.
    MeSH term(s) Activin Receptors, Type II/therapeutic use ; Anemia/drug therapy ; Anemia/pathology ; Animals ; Hematinics/therapeutic use ; Humans ; Immunoglobulin Fc Fragments/therapeutic use ; Myelodysplastic Syndromes/drug therapy ; Myelodysplastic Syndromes/pathology ; Recombinant Fusion Proteins/therapeutic use ; Transforming Growth Factor beta/metabolism
    Chemical Substances Hematinics ; Immunoglobulin Fc Fragments ; Recombinant Fusion Proteins ; Transforming Growth Factor beta ; luspatercept (AQK7UBA1LS) ; Activin Receptors, Type II (EC 2.7.11.30)
    Language English
    Publishing date 2020-07-30
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 752396-8
    ISSN 1873-5835 ; 0145-2126
    ISSN (online) 1873-5835
    ISSN 0145-2126
    DOI 10.1016/j.leukres.2020.106430
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1321: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Myelodysplastic syndromes: a review of therapeutic progress over the past 10 years.

    Feld, Jonathan / Belasen, Abigail / Navada, Shyamala C

    Expert review of anticancer therapy

    2020  Volume 20, Issue 6, Page(s) 465–482

    Abstract: Introduction: Myelodysplastic syndromes (MDS) represent a range of bone marrow disorders, with patients affected by cytopenias and risk of progression to AML. There are limited therapeutic options available for patients, including hypomethylating agents ...

    Abstract Introduction: Myelodysplastic syndromes (MDS) represent a range of bone marrow disorders, with patients affected by cytopenias and risk of progression to AML. There are limited therapeutic options available for patients, including hypomethylating agents (azacitidine/decitabine), growth factor support, lenalidomide, and allogeneic stem cell transplant.
    Areas covered: This review provides an overview of the progress made over the past decade for emerging therapies for lower- and higher-risk MDS (MDS-HR). We also cover advances in prognostication, supportive care, and use of allogeneic SCT in MDS.
    Expert opinion: While there have been no FDA-approved therapies for MDS in the past decade, we anticipate the approval of luspatercept based on results from the MEDALIST trial for patients with lower-risk MDS (MDS-LR) and ringed sideroblasts who have failed or are ineligible for erythropoiesis stimulating agents (ESAs). With growing knowledge of the biologic and molecular mechanisms underlying MDS, it is anticipated that new therapies will be approved in the coming years.
    MeSH term(s) Animals ; Antineoplastic Agents/administration & dosage ; Disease Progression ; Humans ; Leukemia, Myeloid, Acute/etiology ; Leukemia, Myeloid, Acute/pathology ; Myelodysplastic Syndromes/pathology ; Myelodysplastic Syndromes/therapy ; Stem Cell Transplantation/methods ; Transplantation, Homologous
    Chemical Substances Antineoplastic Agents
    Language English
    Publishing date 2020-06-01
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2112544-2
    ISSN 1744-8328 ; 1473-7140
    ISSN (online) 1744-8328
    ISSN 1473-7140
    DOI 10.1080/14737140.2020.1770088
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5907: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Forsaken Pharmaceutical: Glasdegib in Acute Myeloid Leukemia and Myeloid Diseases.

    Feld, Jonathan / Silverman, Lewis R / Navada, Shyamala C

    Clinical lymphoma, myeloma & leukemia

    2020  Volume 21, Issue 4, Page(s) e415–e422

    Abstract: Advancements in the understanding of the pathogenesis of acute myeloid leukemia (AML) have led to the introduction and approval of a number of novel drugs in AML. Glasdegib, an oral hedgehog pathway inhibitor, was approved in 2018 in combination with low- ...

    Abstract Advancements in the understanding of the pathogenesis of acute myeloid leukemia (AML) have led to the introduction and approval of a number of novel drugs in AML. Glasdegib, an oral hedgehog pathway inhibitor, was approved in 2018 in combination with low-dose cytarabine for the treatment of newly diagnosed AML in patients unfit for intensive chemotherapy. In this review, we discuss the preclinical rationale for glasdegib, important clinical trials that led to glasdegib's approval, and future trials of glasdegib in AML and other myeloid diseases. Notably, 2 large randomized, placebo-controlled phase 3 trials (AML BRIGHT 1019) are currently recruiting patients with newly diagnosed AML to evaluate glasdegib in combination with intensive chemotherapy or azacitidine, depending on the patient's ability to tolerate induction chemotherapy. While glasdegib and low-dose cytarabine have been eclipsed by venetoclax and hypomethylating agent combinations for newly diagnosed AML in the United States, we discuss other areas where glasdegib may still have an opportunity to improve outcomes in this devastating disease.
    MeSH term(s) Animals ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Azacitidine/therapeutic use ; Benzimidazoles/pharmacology ; Benzimidazoles/therapeutic use ; Cell Line, Tumor ; Clinical Trials as Topic ; Cytarabine/therapeutic use ; Drug Approval ; Drug Evaluation, Preclinical ; Humans ; Induction Chemotherapy/adverse effects ; Induction Chemotherapy/methods ; Leukemia, Myeloid, Acute/drug therapy ; Mice ; Phenylurea Compounds/pharmacology ; Phenylurea Compounds/therapeutic use ; Signal Transduction/drug effects ; Smoothened Receptor/antagonists & inhibitors ; Smoothened Receptor/metabolism ; United States
    Chemical Substances Benzimidazoles ; Phenylurea Compounds ; SMO protein, human ; Smoothened Receptor ; Cytarabine (04079A1RDZ) ; glasdegib (K673DMO5H9) ; Azacitidine (M801H13NRU)
    Language English
    Publishing date 2020-12-16
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2540992-X
    ISSN 2152-2669 ; 2152-2650
    ISSN (online) 2152-2669
    ISSN 2152-2650
    DOI 10.1016/j.clml.2020.12.007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5903: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top